Nicotinamide
metaboliteNicotinamide reflects altered NAD+ metabolism and energetic stress during myocardial ischemia.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleNAD+ precursor; systemic metabolic marker reflecting ischemic energetic stress but not atherothrombotic mechanism.
Druggability
Not assessed (no mapped human gene target).
Type I vs non-Type I discrimination
ScoresIndeterminate
R — rupture / Type-I—
C — non-Type-I44
A — assay feasibility42
E — evidence strength86
T1DI (composite)13
Specificity differential (R−C)-29.4
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationn/a
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuren/a
2hypertensive emergencymag 0
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 2
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 1
Coverage: 6/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 8 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Combining the Strengths of the Explainable Boosting Machine and Metabolomics Approaches for Biomarker Discovery in Acute Myocardial Infarction.Diagnostics (Basel, Switzerland) · 2024 · PMID 39001243 · doi
Clinical trials(1)
- Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in PsoriasisNCT04271735 · NA · COMPLETED · Niagen, Placebo